Search results
Showing 1636 to 1650 of 9127 results
Evidence-based recommendations on mepolizumab (Nucala) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis (TA1155)
Evidence-based recommendations on rozanolixizumab (Rystiggo) for treating antibody-positive generalised myasthenia gravis in adults.
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when a stem cell transplant is unsuitable.
NICE is unable to make a recommendation on imlunestrant (Inluriyo) for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1168
NICE is unable to make a recommendation on nogapendekin alfa inbakicept (Anktiva) with Bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumours, that is unresponsive to BCG in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1163
Inebilizumab for treating immunoglobulin G4-related disease (terminated evaluation) (TA1151)
NICE is unable to make a recommendation on inebilizumab (Uplizna) for immunoglobulin G4-related disease. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1151
Evidence-based recommendations on atogepant (Aquipta) for the acute treatment of migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation) (TA1180)
NICE is unable to make a recommendation on netarsudil (Rhokiinsa) for treating open-angle glaucoma or ocular hypertension in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1180
Evidence-based recommendations on deuruxolitinib (Leqselvi) for treating severe alopecia areata in adults.
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer (TA1177)
Evidence-based recommendation on pembrolizumab (Keytruda) with chemoradiotherapy for untreated locally advanced cervical cancer in adults.
Show all sections
NICE is unable to make a recommendation on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer in adults who have had anti-androgen treatment but have not had a taxane. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1179
Evidence-based recommendation on mirvetuximab soravtansine (Elahere) for treating folate receptor-alpha (FR-alpha)-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.